NCT07612930 — Anda Biopharmaceutical Development… cancer immunotherapy trial
Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy
Registry record
| Registry ID | NCT07612930 ↗ |
|---|---|
| Lead sponsor | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. |
| Collaborators | — |
| Phase | — |
| Status | Available |
| Indication | Pancreatic Ductal Adenocarcinoma (PDAC) |
| Enrollment | — |
| Start date | — |
| Primary completion | — |
| Last registry update | 29 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07612930), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07612930?
NCT07612930 (Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Anda Biopharmaceutical Development (Shenzhen) Co., Ltd..
Is NCT07612930 recruiting?
As of the 2026-05-29 registry update, NCT07612930 is listed as "Available". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07612930?
The lead sponsor is Anda Biopharmaceutical Development (Shenzhen) Co., Ltd..
What condition does NCT07612930 study?
The registered condition is Pancreatic Ductal Adenocarcinoma (PDAC). Primary completion is listed as not listed.
Are results available for NCT07612930?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07612930.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.